Welton O’Neal

420 total citations
23 papers, 284 citations indexed

About

Welton O’Neal is a scholar working on Psychiatry and Mental health, Pediatrics, Perinatology and Child Health and Cognitive Neuroscience. According to data from OpenAlex, Welton O’Neal has authored 23 papers receiving a total of 284 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Psychiatry and Mental health, 7 papers in Pediatrics, Perinatology and Child Health and 6 papers in Cognitive Neuroscience. Recurrent topics in Welton O’Neal's work include Attention Deficit Hyperactivity Disorder (8 papers), Epilepsy research and treatment (5 papers) and Pharmacological Effects and Toxicity Studies (4 papers). Welton O’Neal is often cited by papers focused on Attention Deficit Hyperactivity Disorder (8 papers), Epilepsy research and treatment (5 papers) and Pharmacological Effects and Toxicity Studies (4 papers). Welton O’Neal collaborates with scholars based in United States, Netherlands and Italy. Welton O’Neal's co-authors include Azmi Nasser, Donald B. Wiest, Paul C. Gillette, Jonathan Rubin, Joseph T. Hull, Gregory D. Busse, Stephen V. Faraone, Phillip A. Tibbs, Roberto Goméni and Jennie García‐Olivares and has published in prestigious journals such as Neurology, American Heart Journal and Clinical Pharmacology & Therapeutics.

In The Last Decade

Welton O’Neal

22 papers receiving 265 citations

Peers

Countries citing papers authored by Welton O’Neal

Since Specialization

Citations

This map shows the geographic impact of Welton O’Neal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Welton O’Neal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Welton O’Neal more than expected).

Fields of papers citing papers by Welton O’Neal

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Welton O’Neal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Welton O’Neal. The network helps show where Welton O’Neal may publish in the future.

Co-authorship network of co-authors of Welton O’Neal

This figure shows the co-authorship network connecting the top 25 collaborators of Welton O’Neal. A scholar is included among the top collaborators of Welton O’Neal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Welton O’Neal. Welton O’Neal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Predicting efficacy of viloxazine extended-release treatment in adults with ADHD using an early change in ADHD symptoms: Machine learning Post Hoc analysis of a phase 3 clinical trial 2022 ·Psychiatry Research ·Stephen V. Faraone, Roberto Goméni, Joseph T. Hull, (unknown), Gregory D. Busse, Zare Melyan, Welton O’Neal, Jonathan Rubin, Azmi Nasser	13
2	The role of placebo response in the efficacy outcome assessment in viloxazine extended‐release pivotal trials in paediatric subjects with attention‐deficit/hyperactivity disorder 2022 ·British Journal of Clinical Pharmacology ·Azmi Nasser, Roberto Goméni, Zhao Wang, Joseph T. Hull, Gregory D. Busse, Zare Melyan, Maurizio Fava, Welton O’Neal, Jonathan Rubin	2
3	Translating Attention-Deficit/Hyperactivity Disorder Rating Scale-5 and Weiss Functional Impairment Rating Scale-Parent Effectiveness Scores into Clinical Global Impressions Clinical Significance Levels in Four Randomized Clinical Trials of SPN-812 (Viloxazine Extended-Release) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder 2021 ·Journal of Child and Adolescent Psychopharmacology ·Azmi Nasser, Alisa R. Kosheleff, Joseph T. Hull, Tesfaye Liranso, (unknown), Gregory D. Busse, Welton O’Neal, Maurizio Fava, Stephen V. Faraone, Jonathan Rubin	12
4	Early response to SPN-812 (viloxazine extended-release) can predict efficacy outcome in pediatric subjects with ADHD: a machine learning post-hoc analysis of four randomized clinical trials 2021 ·Psychiatry Research ·Stephen V. Faraone, Roberto Goméni, Joseph T. Hull, Gregory D. Busse, Zare Melyan, Welton O’Neal, Jonathan Rubin, Azmi Nasser	23
5	Viloxazine in the Management of CNS Disorders: A Historical Overview and Current Status 2021 ·CNS Drugs ·Robert L. Findling, (unknown), Azmi Nasser, Stefan Schwabe, Chung‐Ping Yu, Jennie García‐Olivares, Welton O’Neal, Jeffrey H. Newcorn	40
6	<p>Predicted Efficacy of Once-Daily Extended-Release Oxcarbazepine (Oxtellar XR®) Monotherapy in Adults and Children with Partial-Onset Seizures: Exposure-Response Modeling and Simulation</p> 2020 ·Clinical Pharmacology Advances and Applications ·(unknown), Roberto Goméni, (unknown), Welton O’Neal, Stefan Schwabe, Azmi Nasser	1
7	Closing the gap: unmet needs of individuals with impulsive aggressive behavior observed in children and adolescents 2020 ·CNS Spectrums ·Adelaide S. Robb, Daniel F. Connor, (unknown), Benedetto Vitiello, (unknown), Welton O’Neal, Stefan Schwabe, Gianpiera Ceresoli‐Borroni, Jeffrey H. Newcorn, (unknown), Jan K. Buitelaar, Robert L. Findling	3
8	Current and future nonstimulants in the treatment of pediatric ADHD: monoamine reuptake inhibitors, receptor modulators, and multimodal agents 2020 ·CNS Spectrums ·Andrew J. Cutler, Gregory W. Mattingly, Rakesh K. Jain, Welton O’Neal	17
9	Adherence with Extended-Release Oxcarbazepine (Oxtellar XR®) vs. Immediate-Release Oxcarbazepine: Analysis of Pooled Data from Four National Pharmacy Claims Databases (P6.293) 2018 ·Neurology ·(unknown), Welton O’Neal, Onur Başer, Li Wang, Joyce A. Cramer	1
10	Real-world assessment of treatment with extended-release topiramate (Trokendi XR^®) and comparison with previous immediate-release topiramate treatment 2018 ·Journal of Comparative Effectiveness Research ·Welton O’Neal, Elizabeth E. Hur, Tesfaye Liranso, (unknown)	3
11	Medical and Pharmacy Claims Analysis Comparing Outcomes with Extended-Release Topiramate (Trokendi XR®) and Immediate-Release Topiramate (P2.169) 2017 ·Neurology ·Welton O’Neal, Elizabeth E. Hur, Tesfaye Liranso, (unknown), (unknown), Ralph M. Turner	1
12	Pragmatic Assessment of Trokendi XR (Extended-Release Topiramate) Use in Clinical Practice (P2.256) 2016 ·Neurology ·Welton O’Neal, Elizabeth E. Hur, Tesfaye Liranso, (unknown)	1
13	Topiramate Pharmacokinetics of Extended-Release Once-Daily SPN-538 (Trokendi XR™) in the Elderly (P3.246) 2014 ·Neurology ·Welton O’Neal, Scott Brittain, (unknown), (unknown), Paolo Baroldi	1
14	Atrial fibrillation and mortality in African American patients with heart failure: Results from the African American Heart Failure Trial (A-HeFT) 2011 ·American Heart Journal ·Judith E. Mitchell, S. William Tam, (unknown), (unknown), Welton O’Neal, Jay N. Cohn, Manuel Worcel	8
15	A retrospective, observational cohort analysis of a nationwide database to compare heart failure prescriptions and related health care utilization before and after publication of updated treatment guidelines in the United States 2010 ·Clinical Therapeutics ·Shirin Shafazand, Yadong Yang, (unknown), Welton O’Neal, Diana Brixner	16
16	The Metabolic Syndrome in African Americans: a review. 2003 ·PubMed ·Wayne Hall, Luther T. Clark, Nanette K. Wenger, (unknown), Shiriki Kumanyika, Karol E. Watson, (unknown), John M. Flack, Keith C. Ferdinand, James R. Gavin, James Reed, Elijah Saunders, Welton O’Neal, (unknown)	58
17	Pharmacokinetics and pharmacodynamics of atenolol in children 1989 ·Clinical Pharmacology & Therapeutics ·Marcia L. Buck, Donald B. Wiest, Paul C. Gillette, (unknown), (unknown), Welton O’Neal	19
18	Comparison of epsilon aminocaproic acid and normal saline for postoperative bladder irrigation following transurethral resection of prostate 1985 ·Urology ·Robert C. Flanigan, Anthony J. Casale, Karen M. Butler, David C. Allen, Welton O’Neal, J. William McRoberts, (unknown)	7
19	Lack of serious toxicity following carbamazepine overdosage 1984 ·American Journal of Health-System Pharmacy ·Welton O’Neal, (unknown), Robert J. Baumann, Robert A. Blouin, (unknown)	8
20	Design of a nuclear-waste package for emplacement in tuff 1983 ·University of North Texas Digital Library (University of North Texas) ·Welton O’Neal, (unknown), D.W. Gregg, (unknown), (unknown), (unknown), (unknown)	0

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact